Leupin Nicolas's Form 4/A amendment
AmendedNovoCure Ltd (NVCR) · filed Mar 3, 2025
- Accession no.
- 0001562180-25-001913
- Filed
- Mar 3, 2025
- Trade date
- Feb 27, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Mar 3, 2025
This filing lists 2 non-derivative transactions. Open-market sales total $19.8K. It was filed 4 days after the trade.
This amendment replaces 0001562180-25-001836 (filed Mar 3, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leupin NicolasCIK 0002007766 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- F2
On February 27, 2025, the reporting person sold 830 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
On the transaction date, the reporting person sold 161 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
Amended to add footnote #1 to the filing.